DNA Repair in Cancer Therapy

ISBN-13: 9781588292988 / Angielski / Twarda / 2004 / 363 str.

Lawrence C. Panasci; Moulay A. Alaoui-Jamali; Lawrence C. Panasci

Opis

A comprehensive review of the recent developments in DNA repair that have potential for translational and clinical applications. The authors explain in detail the various mechanisms by which cancer cells can circumvent anticancer therapy and limits its usefulness in patients. They also review the clinical impact of such novel inhibitors of DNA repair mechanisms as methylguanine-DNA-methyltransferase. Also examined are inhibitors of other DNA repair enzymes such as PARP and DNA-PK, now under development and close to clinical trials. The book captures-for both cancer researchers and practicing oncologists dealing with hallmark "relapse" or "drug resistance" phenomena on a daily basis-the many exciting new uses of DNA repair inhibitors, either alone or in combination with anticancer therapies.

Recenzje

...gives a comprehensive review of the modern status of the DNA repair field for cancer researchers and clinical practitioners and provides a solid basis for in-depth study of different areas in this field...The book is a timely publication with a significant intended audience that will be served well. The book is well planned, well written, comprehensive, and addresses recent findings in the field. -Doody's Health Sciences Book Review Journal

"...extensive and extremely detailed...a comprehensive review of DNA repair." - The Annals of Pharmacotherapy

"Comprehensive and cutting-edge, for both cancer researchers and practicing oncologists dealing with the hallmark 'relapse; or 'drug resistance' phenomena on a daily basis...." Tumori

Spis treści

Clinical Resistance to Alkylators: Status and Perspective Brian Leyland-Jones Role of Nonhomologous End-Joining and Recombinational DNA Repair in Resistance to Nitrogen Mustard and DNA Crosslinking Agents Lawrence C. Panasci, Zhi-Yuan Xu, and Raquel Aloyz Repair of DNA Interstrand Crosslinks Produced by Cancer Chemotherapeutic Drugs Peter J. McHugh and John A. Hartley Chemosensitization to Platinum-Based Anticancer Drugs: Current Trends and Future Prospects Bertrand J. Jean-Claude Regulation of DNA Repair and Apoptosis by p53 and Its Impact on Alkylating Drug Resistance of Tumor Cells Istvan Boldogh, Kishor K. Bhakat, Dora Bocangel, Gokul C. Das, and Sankar Mitra Stress-Activated Signal Transduction Pathways in DNA Damage Response: Implications for Repair, Arrest, and Therapeutic Interventions Moulay A. Alaoui-Jamali, P. James Scrivens, and Martin Loignon Overcoming Resistance to Alkylating Agents by Inhibitors of O6-Alkylguanine-DNA Alkyltransferase Anthony E. Pegg and M. Eileen Dolan Cellular Protection Against the Antitumor Drug Bleomycin Dindial Ramotar, Huijie Wang, and Chaunhua He Potential Role of PARP Inhibitors in Cancer Treatment and Cell Death Michèle Rouleau and Guy G. Poirier Relationship Among DNA Repair Genes, Cellular Radiosensitivity, and the Response of Tumors and Normal Tissues to Radiotherapy David Murray and Adrian C. Begg Strand-Break Repair and Radiation Resistance George Shenouda V(D)J Recombination and DNA Double-Strand-Break Repair: From Immune Deficiency to Tumorigenesis Despina Moshous and Jean-Pierre de Villartay Inherited Disorders of Genomic Instability and Cancer Susceptibility Gary M. Kupfer Role of BRCA1 and BRCA2 in DNA Repair and Potential Impact on Therapeutics Razqallah Hakem Genetic Variations in DNARepair: Their Implications in Human Cancer Risk, Prevention, and Therapy Jennifer J. Hu Index

Blurb

Because of drug resistance, currently available anticancer therapies-drugs, radiotherapy, and other biological agents-have limited efficacy in treating cancer. In DNA Repair in Cancer Therapy, leading cancer researchers and oncologists comprehensively review the many recent developments in DNA repair that have potential for translational and clinical applications. The authors explain in detail the various mechanisms by which cancer cells can circumvent anticancer therapy and limit its usefulness in patients. They also review the clinical impact of such novel inhibitors of DNA repair mechanisms as methylguanine-DNA-methyltransferase. Inhibitors of such other DNA repair enzymes as PARP and DNA-PK, now under development and close to clinical trials, are also examined.
Comprehensive and cutting-edge, DNA Repair in Cancer Therapy surveys-for both cancer researchers and practicing oncologists dealing with hallmark "relapse" or "drug resistance" phenomena on a daily basis-the many exciting new uses of DNA repair inhibitors, either alone or in combination with anticancer therapies.